An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease

Mario Cazzola,1 Josuel Ora,2 Francesco Cavalli,1 Paola Rogliani,1,2 Maria Gabriella Matera3 1Chair of Respiratory Medicine, Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy; 2Division of Respiratory Medicine, University Hospital Tor Vergata, Rome, Italy; 3Chair of Pha...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cazzola M, Ora J, Cavalli F, Rogliani P, Matera MG
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	copd monoclonal antibodies pheno/endotypic pathways anti–t1-mediated inflammation mabs anti–t2-mediated inflammation mabs Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/b877eba557124db2b2b32274aeae2752
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b877eba557124db2b2b32274aeae2752
record_format	dspace
spelling	oai:doaj.org-article:b877eba557124db2b2b32274aeae27522021-12-02T18:56:49ZAn Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease1177-5491https://doaj.org/article/b877eba557124db2b2b32274aeae27522021-08-01T00:00:00Zhttps://www.dovepress.com/an-overview-of-the-safety-and-efficacy-of-monoclonal-antibodies-for-th-peer-reviewed-fulltext-article-BTThttps://doaj.org/toc/1177-5491Mario Cazzola,1 Josuel Ora,2 Francesco Cavalli,1 Paola Rogliani,1,2 Maria Gabriella Matera3 1Chair of Respiratory Medicine, Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy; 2Division of Respiratory Medicine, University Hospital Tor Vergata, Rome, Italy; 3Chair of Pharmacology, Department of Experimental Medicine, University of Campania Luigi Vanvitelli, Naples, ItalyCorrespondence: Mario Cazzola Email mario.cazzola@uniroma2.itAbstract: Several mAbs have been tested or are currently under clinical evaluation for the treatment of COPD. They can be subdivided into those that aim to block specific pro-inflammatory and pro-neutrophilic cytokines and chemokines, such as TNF-α, IL-1β, CXCL8 and IL-1β, and those that act on T2-mediated inflammation, respectively, by blocking IL-5 and/or its receptor, preventing IL-4 and IL-13 signaling, affecting IL-33 pathway and blocking TSLP. None of these approaches has proved to be effective, probably because in COPD there is no dominant cytokine or chemokine and, therefore, a single mAb cannot be effective on all pathways. With a more in-depth understanding of the numerous pheno/endotypic pathways that play a role in COPD, it may eventually be possible to identify those specific patients in whom some of these cytokines or chemokines might predominate. In this case, it will be possible to implement a personalized treatment, but the use of each mAb will only be reserved for a very limited number of subjects.Keywords: COPD, monoclonal antibodies, pheno/endotypic pathways, anti–T1-mediated inflammation mAbs, anti–T2-mediated inflammation mAbsCazzola MOra JCavalli FRogliani PMatera MGDove Medical Pressarticlecopdmonoclonal antibodiespheno/endotypic pathwaysanti–t1-mediated inflammation mabsanti–t2-mediated inflammation mabsMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 15, Pp 363-374 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	copd monoclonal antibodies pheno/endotypic pathways anti–t1-mediated inflammation mabs anti–t2-mediated inflammation mabs Medicine (General) R5-920
spellingShingle	copd monoclonal antibodies pheno/endotypic pathways anti–t1-mediated inflammation mabs anti–t2-mediated inflammation mabs Medicine (General) R5-920 Cazzola M Ora J Cavalli F Rogliani P Matera MG An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease
description	Mario Cazzola,1 Josuel Ora,2 Francesco Cavalli,1 Paola Rogliani,1,2 Maria Gabriella Matera3 1Chair of Respiratory Medicine, Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy; 2Division of Respiratory Medicine, University Hospital Tor Vergata, Rome, Italy; 3Chair of Pharmacology, Department of Experimental Medicine, University of Campania Luigi Vanvitelli, Naples, ItalyCorrespondence: Mario Cazzola Email mario.cazzola@uniroma2.itAbstract: Several mAbs have been tested or are currently under clinical evaluation for the treatment of COPD. They can be subdivided into those that aim to block specific pro-inflammatory and pro-neutrophilic cytokines and chemokines, such as TNF-α, IL-1β, CXCL8 and IL-1β, and those that act on T2-mediated inflammation, respectively, by blocking IL-5 and/or its receptor, preventing IL-4 and IL-13 signaling, affecting IL-33 pathway and blocking TSLP. None of these approaches has proved to be effective, probably because in COPD there is no dominant cytokine or chemokine and, therefore, a single mAb cannot be effective on all pathways. With a more in-depth understanding of the numerous pheno/endotypic pathways that play a role in COPD, it may eventually be possible to identify those specific patients in whom some of these cytokines or chemokines might predominate. In this case, it will be possible to implement a personalized treatment, but the use of each mAb will only be reserved for a very limited number of subjects.Keywords: COPD, monoclonal antibodies, pheno/endotypic pathways, anti–T1-mediated inflammation mAbs, anti–T2-mediated inflammation mAbs
format	article
author	Cazzola M Ora J Cavalli F Rogliani P Matera MG
author_facet	Cazzola M Ora J Cavalli F Rogliani P Matera MG
author_sort	Cazzola M
title	An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease
title_short	An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease
title_full	An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease
title_fullStr	An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease
title_full_unstemmed	An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease
title_sort	overview of the safety and efficacy of monoclonal antibodies for the chronic obstructive pulmonary disease
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/b877eba557124db2b2b32274aeae2752
work_keys_str_mv	AT cazzolam anoverviewofthesafetyandefficacyofmonoclonalantibodiesforthechronicobstructivepulmonarydisease AT oraj anoverviewofthesafetyandefficacyofmonoclonalantibodiesforthechronicobstructivepulmonarydisease AT cavallif anoverviewofthesafetyandefficacyofmonoclonalantibodiesforthechronicobstructivepulmonarydisease AT roglianip anoverviewofthesafetyandefficacyofmonoclonalantibodiesforthechronicobstructivepulmonarydisease AT materamg anoverviewofthesafetyandefficacyofmonoclonalantibodiesforthechronicobstructivepulmonarydisease AT cazzolam overviewofthesafetyandefficacyofmonoclonalantibodiesforthechronicobstructivepulmonarydisease AT oraj overviewofthesafetyandefficacyofmonoclonalantibodiesforthechronicobstructivepulmonarydisease AT cavallif overviewofthesafetyandefficacyofmonoclonalantibodiesforthechronicobstructivepulmonarydisease AT roglianip overviewofthesafetyandefficacyofmonoclonalantibodiesforthechronicobstructivepulmonarydisease AT materamg overviewofthesafetyandefficacyofmonoclonalantibodiesforthechronicobstructivepulmonarydisease
_version_	1718377290748919808

An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease

Ejemplares similares